Vyvanse’s Long Shadow: Launch To Decide Fate Of Two Other Shire NDAs
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Shire is keeping two pending NDAs for new attention deficit hyperactivity disorder treatments in a sort of limbo while it waits to see if the high expectations for the launch of its d-amphetamine prodrug Vyvanse are fulfilled